Screener
TG Therapeutics TGTX CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | Six months ended / June 30, 2026 | Six months ended / June 30, 2025 |
|---|---|---|
| Proceeds from maturity of held-to-maturity securities | 29,000 | 129,750 |
| Investment in held-to-maturity securities | (37,490) | (145,359) |
| Purchases of equity investments | — | (1,250) |
| Purchases of property, plant and equipment | (344) | (67) |
| Net cash used in investing activities | (8,834) | (16,926) |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Payment of loan payable | (255,000) | — |
| Proceeds from exercise of options | 848 | 453 |
Document
FAQ
- What is TG Therapeutics's capex?
- TG Therapeutics (TGTX) reported capex of $293K in Q2 2026.
- How has TG Therapeutics's capex changed year-over-year?
- TG Therapeutics's capex increased by 597.6% year-over-year, from $42K to $293K.
- What is the long-term trend for TG Therapeutics's capex?
- Over 3 years (2021 to 2025), TG Therapeutics's capex has grown at a -18.9% compound annual growth rate (CAGR), from $401K to $214K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about TG Therapeutics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude